SCHEMBL8201715

SCHEMBL8201715

Cn1c(C(N)=O)cc2c(Br)cccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.50
EGFR P00533 3/20 0.45
SRC P12931 1/20 0.45
KDM4E B2RXH2 4/20 0.40
PARP1 P09874 1/20 0.40
MCL1 Q07820 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GPR3 P46089 1/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 3/20 0.38
BRD4 O60885 1/20 0.38
BRPF1 P55201 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 3/20 0.38
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306325 0.85 MCL1 (0.56) SLC9A1EGFRSRCKDM4EMCL1
SCHEMBL5005344 0.82 SLC9A1 (0.51) SLC9A1EGFRSRCKDM4EPARP1
SCHEMBL3561006 0.81 KDM4E (0.51) SLC9A1EGFRSRCKDM4EGPR3
SCHEMBL29977346 0.79 HPGD (0.53) SLC9A1EGFRSRCKDM4EMCL1
SCHEMBL23809377 0.78 SLC9A1 (0.48) SLC9A1EGFRSRCKDM4EMCL1
SCHEMBL2322049 0.78 SLC9A1 (0.48) SLC9A1KDM4EPARP1KMT2AALDH1A1
SCHEMBL22042092 0.78 KDM4E (0.50) SLC9A1KDM4EKMT2AALDH1A1HSD17B10
SCHEMBL2323444 0.73 MCL1 (0.71) SLC9A1MCL1MEN1KMT2A
SCHEMBL31426224 0.72 DAO (0.56) KDM4EMEN1KMT2AALDH1A1HSD17B10
SCHEMBL25209466 0.72 KMT2A (0.48) EGFRSRCKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12144816-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2024-11-19 US disclosed
EP-4292662-A2 SUBSTITUTED INDOLE MCL-1 INHIBITORS Vanderbilt University (US) 2023-12-20 EP disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
EP-3423435-B1 SUBSTITUTED INDOLE MCL-1 INHIBITORS UNIV VANDERBILT (US) 2023-08-23 EP disclosed
US-11596639-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2023-03-07 US disclosed
CN-109153643-B Substituted indole MCL-1 inhibitors 范德比尔特大学 2022-06-21 CN disclosed
US-20210283138-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2021-09-16 US disclosed
EP-3423435-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS Vanderbilt University (US) 2019-01-09 EP disclosed
WO-2008057209-A1 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210283138-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 SLC9A1 3587/4885EGFR 1422/4885SRC 233/4885
US-12144816-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 SLC9A1 3587/4885EGFR 1422/4885SRC 233/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 SLC9A1 3587/4885EGFR 1422/4885SRC 233/4885
US-11596639-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 SLC9A1 3587/4885EGFR 1422/4885SRC 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.